Share
19,189 Posts.
lightbulb Created with Sketch. 6189
clock Created with Sketch. 25/06/22
13:14
Share
Originally posted by valueadd
↑
"MELBOURNE, AUSTRALIA (24 June 2022): Hexima Limited (ASX:HXL) announces that based on its preliminary review, the results of its phase II clinical study of pezadeftide for the treatment of onychomycosis (HXP124-ONY-002) are inconclusive and will require further detailed investigation and evaluation. The results seen in this study do not appear to correlate with results observed in its prior phase I study (HXP124-ONY-001) and do not support moving directly into a phase III program. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete". We are very sorry it was all crap - but we had fun whilst it lasted ? & we hereby tender out resignation. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete".
Expand
You put the company into a trading halt until you can provide the shareholders with the information they need to make an informed decision. All that releasing vague announcements with no details accomplishes is to create shareholder panic destroying shareholder value.
(20min delay)